All In Biotech

Drug Trial Radar · NCT00330668

Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency

Recombinant Human Insulin-Like Growth Factor-1 (IGF-1) Treatment of Children With Growth Failure Associated With Primary IGF-1 Deficiency: An Open-Label, Multi-Center, Extension Study

Last checked: Nov 20, 2026Latest source record: Aug 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

114

Actual

Start

Nov 2005

Primary completion

Feb 2010

Study completion Mar 2010

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
May 29, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 4 years, up to 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an extension study to Tercica study MS301 (NCT00125164) and is intended to collect long term safety and efficacy data on the continued use of recombinant human insulin-like growth factor-1 (rh IGF-1) in children and adolescents treated for primary IGF-1 deficiency (IGFD). The secondary objective is to use the data collected to learn more about the relationship of IGF-1 exposure to the promotion of normal growth and pubertal development.

Conditions

  • Growth Disorders

Interventions

  • rh IGF-1 (mecasermin)Drug

    Patients from untreated arm for prior study MS301 (NCT00125164) were randomized to a dose of either 80 or 120 mcg/kg twice daily. For patients receiving active treatment in previous study MS 301 (NCT00125164), they started on a dose of 80 or 120 mcg/kg twice daily based on the dose reached at end of the previous study. Following a protocol amendment in May 2009, all patients were switched to once daily doses of 160 µg/kg, escalated to a targeted maximum dose of 240 µg/kg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Height Velocity During BID Dosing PeriodTime frame: At Years 1, 2 and 3 in BID dosing period.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ipsen

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.